The Protecting Life and Integrity in Research Act of 2025 prohibits any Federal department, agency, or office from conducting, funding, approving, or otherwise supporting research that uses human fetal tissue obtained pursuant to an induced abortion. It also amends the Public Health Service Act to confine federally supported fetal‑tissue research to tissue obtained after a miscarriage or stillbirth, revises statutory definitions for miscarriage and stillbirth, and repeals a prior NIH statutory note.
The bill adds an explicit ban on soliciting or knowingly acquiring donations of fetal tissue when the donor or acquirer knows the tissue came from an induced abortion or from a pregnancy deliberately initiated to provide tissue.
For research managers, compliance officers, and institutional counsel, the bill redirects where federally supported fetal‑tissue work may occur, creates new provenance and documentation risks, and leaves open enforcement and verification questions. It also carves an affirmative exception for developing new, high‑efficiency cell lines not derived from fetal tissue obtained via induced abortion — a narrow path for vaccine and vector developers who can use non‑fetal sources.
At a Glance
What It Does
The bill bars federal departments, agencies, and offices from conducting, funding, approving, or otherwise supporting research that uses human fetal tissue obtained pursuant to an induced abortion. It amends section 498A of the Public Health Service Act to limit federally supported fetal‑tissue research to tissue obtained after a miscarriage or stillbirth, and it amends section 498B to prohibit soliciting or knowingly acquiring donations when the donor or recipient knows the tissue came from an induced abortion or a pregnancy initiated to provide such tissue.
Who It Affects
Directly affected parties include federal grantmakers (NIH and related agencies), academic and private research labs using fetal tissue, tissue procurement organizations, and biotech firms that rely on fetal‑tissue‑derived cell lines or collaborations funded by federal dollars. Institutional compliance and grants offices will face immediate obligations to reassess active awards and applications that involve fetal tissue from elective abortions.
Why It Matters
This bill closes a statutory route for federally supported research using tissue from elective abortions and channels federal support toward tissue from miscarriage or stillbirth only. For federally funded science, that is a supply‑side restriction: it narrows permissible biological materials, raises provenance and documentation burdens, and could shift some work to private funding or non‑U.S. collaborations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a clear, statutory prohibition: any Federal department, agency, or office may not conduct, fund, approve, or otherwise support research that uses human fetal tissue if that tissue was obtained pursuant to an induced abortion. That prohibition is broad in verbs — conduct, fund, approve, support — meaning grants, contracts, intramural projects, and agency‑sponsored approvals are all captured.
At the same time, the bill preserves a narrow route for federally supported fetal‑tissue research: it amends section 498A of the Public Health Service Act to explicitly permit federally supported research only on tissue obtained after a miscarriage or a stillbirth, and it supplies statutory definitions for 'miscarriage' (under 20 weeks) and 'stillbirth' (20 weeks or more). The bill also repeals Section 113 of the NIH Revitalization Act of 1993, removing a prior statutory note that touched on fetal‑tissue policy.To prevent circumvention, the bill strengthens the donation prohibition in section 498B of the PHSA: it bans soliciting or knowingly acquiring a donation of human fetal tissue when the acquirer knows the tissue was obtained pursuant to an induced abortion or that a pregnancy was intentionally initiated to provide tissue.
The bill excludes routine transfers for autopsy or burial from that donation ban, but otherwise criminal‑style mens‑rea language ("knowing") is central to enforcement questions.Finally, the bill expressly preserves agency authority to develop or support 'new, high‑efficiency cell lines' — including for vaccines and genetic vectors — provided those cell lines are not derived from fetal tissue obtained from induced abortions. In practice that means federally supported commercial or academic development of alternative cell platforms remains permissible if their derivation avoids the banned source.
The Five Things You Need to Know
The bill bans Federal departments, agencies, and offices from conducting, funding, approving, or otherwise supporting research that uses human fetal tissue obtained pursuant to an induced abortion.
It rewrites 42 U.S.C. 289g–1 (section 498A of the PHSA) to permit federally supported fetal‑tissue research only when the tissue was obtained after a miscarriage (defined as <20 weeks) or a stillbirth (defined as ≥20 weeks).
Section 3 amends 42 U.S.C. 289g–2 (section 498B) to prohibit soliciting or knowingly acquiring, receiving, or accepting donations of fetal tissue when the person knows the tissue came from an induced abortion or from a pregnancy deliberately initiated to provide tissue (with an exclusion for transfers for autopsy or burial).
The bill preserves federal authority to develop or support new, high‑efficiency cell lines for vaccines and genetic vectors — but only if those cell lines are not derived from fetal tissue obtained from induced abortions.
The legislation repeals the note added by section 113 of the NIH Revitalization Act of 1993, removing that statutory language as part of the reconfiguration of federal fetal‑tissue policy.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Identifies the act as the "Protecting Life and Integrity in Research Act of 2025." This is a formal label but signals legislative intent to reframe federal policy on fetal‑tissue research toward ethical sourcing and away from tissue derived from elective abortions.
Broad federal prohibition on fetal tissue from induced abortions
This clause bars any federal department, agency, or office from conducting, funding, approving, or otherwise supporting research that uses human fetal tissue obtained pursuant to an induced abortion. Because the verbs include funding and approval, the provision applies to extramural grants, contracts, intramural projects, and any administrative approvals that enable research. Agencies will need to interpret "support" in policy terms (e.g., grant admin, cooperative agreements, in‑kind services).
Exception for non‑fetal‑derived cell line development
The statute carves out an affirmative exception: federal agencies may develop or support new, high‑efficiency cell lines (for vaccines and genetic vectors) so long as those lines are not derived from fetal tissue obtained via induced abortion. Practically, that creates a compliance pathway for vaccine and gene‑therapy work that can demonstrate non‑fetal derivation and traceability of cell‑line ancestry.
Amendments to PHSA section 498A and definitions
The bill revises 498A to expressly limit federally supported fetal‑tissue research to tissue obtained after a miscarriage or stillbirth, changes the section heading to reflect that limit, and provides statutory definitions for "human fetal tissue," "miscarriage" (<20 weeks), and "stillbirth" (≥20 weeks). By defining "human fetal tissue" to include tissue from induced abortion, miscarriage, or stillbirth while separately prohibiting use of tissue from induced abortions, the text intentionally isolates permissible sources to miscarriage or stillbirth under the amended 498A framework.
Ban on solicitation and knowing acquisition of donation of tissue from induced abortions; PHSA 498B edits
Section 3 amends PHSA 498B to prohibit soliciting or knowingly acquiring, receiving, or accepting a donation of human fetal tissue when the acquirer knows the tissue came from an induced abortion or a pregnancy deliberately initiated to provide such tissue. It excludes transfers for autopsy or burial. The section also makes conforming reorganizations of 498B's subsections. The repeated use of "knowing" places evidentiary weight on intent and knowledge in any enforcement context.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Anti‑abortion and pro‑life advocacy organizations — the bill codifies restrictions they seek on federal support for research using tissue from elective abortions and creates statutory language supporting ethical sourcing claims.
- Patients and patient‑advocacy groups concerned about the ethics of tissue provenance — the law narrows federal support to miscarriage and stillbirth sources, which some stakeholders view as ethically preferable.
- Biotech firms and academic groups developing alternative cell lines — the bill expressly preserves federal support for 'new, high‑efficiency cell lines' not derived from prohibited fetal sources, creating a targeted commercial opportunity for alternatives to fetal‑tissue‑derived platforms.
Who Bears the Cost
- Academic and private researchers using fetal tissue from elective abortions — they will lose access to federal funding and approvals for projects reliant on that material and must revalidate studies with alternative materials or private funds.
- NIH and other federal agencies — agencies will face programmatic adjustments, grant reissuances, and compliance and contract modifications to remove or reclassify prohibited work and to screen proposals for tissue provenance.
- Tissue procurement organizations and clinical partners that supplied tissue from elective abortions — they risk loss of federal customers, must change consent and documentation practices, and may face reduced demand for certain donation channels.
- Institutions with ongoing collaborations or international partnerships — universities and companies engaging in cross‑border research that mixes federal and non‑federal funds will face complex compliance lines and potential ineligibility for federal support when a prohibited tissue source is involved.
Key Issues
The Core Tension
The central tension is between an ethical restriction on using tissue from induced abortions — prioritizing source‑based moral judgments and public confidence — and the practical scientific need for certain biological materials that have historically enabled vaccine, transplant, and basic developmental research; the bill protects ethical concerns but risks narrowing scientific options, shifting research outside federal purview, and creating hard verification questions about what counts as "knowing" acquisition.
The bill creates a provenance‑heavy compliance regime without spelling out verification or audit procedures. "Knowing" acquisition and solicitation standards hinge on evidence of knowledge — a high bar in some transactions — but institutions will nonetheless need robust donor‑consent, chain‑of‑custody, and recordkeeping practices to avoid jeopardizing federal support. The statute leaves enforcement mechanisms to existing agency authorities; it does not create a detailed inspection, reporting, or penalty regime, which means guidance and implementing rules will determine how strictly agencies police sources and what documentary proof suffices.
Operationally, the supply of permissible tissue (miscarriage or stillbirth) is limited and often clinically and ethically distinct from tissue from elective abortions. That raises scientific trade‑offs: some experiments rely on biological properties specific to elective‑abortion–sourced tissue, and substituting other sources may not be scientifically equivalent.
The exception for developing new, high‑efficiency cell lines is forward‑looking but narrow — it depends on successful development and federal acceptance of non‑fetal derivations, which could be slow and costly. Finally, the bill could push some research to private funders or foreign partners, creating regulatory arbitrage and complicating oversight of translational projects that mix funding sources.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.